Scholar Rock – 2025-11-18 - Increase Confidence 8/10

SRRK – Increase in Days/Weeks

Scholar Rock reported a widening net loss of $102.2M in Q3 2025 and negative free cash flow of $201M TTM, yet recently completed a constructive Type A meeting with the FDA on November 12th regarding apitegromab’s BLA resubmission.

Why This Matters

Despite deteriorating near-term financials driven by launch readiness costs, the market is focused on imminent regulatory and commercial catalysts—particularly the anticipated 2026 U.S. launch of apitegromab for spinal muscular atrophy—making valuation less dependent on current profitability and more on clinical and regulatory momentum.

Key Insights

• Cash Runway: $369.6M in cash, sufficient into 2027, with $60M additional funding expected from warrant exercises
• News Impact: FDA Type A meeting completed Nov 12; BLA resubmission and U.S. launch expected in 2026, with European decision by mid-2026
• Risk/Offset: High operating losses and G&A spike ($53.1M vs $16.1M YoY) reflect commercial prep but increase cash burn risk if launch delays

Practical Implications

• Bull Case: Positive FDA feedback and clear path to approval could trigger re-rating toward $46.55 fair value (17% upside) in weeks
• Bear Case: Regulatory setbacks or manufacturing delays could spark sell-off back toward $32–$34 range
• Confidence: 8/10 – Strong analyst sentiment and defined regulatory timeline support near-term upside

Prediction: increase

Reference:

• https://finance.yahoo.com/news/scholar-rock-reports-third-quarter-120000090.html
• https://finance.yahoo.com/news/scholar-rock-srrk-fda-progress-181410926.html